Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof
AssigneePeptron, Inc.
InventorHo Il Choi
Life of this patent
Estimating the term…
Abstract
A GLP-1 receptor agonist has effects of reducing serious side effects due to long-term use of levodopa when administered in combination with levodopa, and also effects of alleviating or improving abnormal involuntary movements (AIMs) caused by levodopa. A method for prevention or treatment of levodopa-induced dyskinesia according to an embodiment of the present disclosure includes administering a glucagon-like peptide-1 (GLP-1) receptor agonist to a patient.
Claims10
A method for treatment of levodopa-induced dyskinesia, the method comprising:
- subcutaneously administering a composition comprising a therapeutically effective amount of a controlled-release formulation of an exendin-4 or exenatide to a patient with the levodopa-induced dyskinesia,
- wherein the controlled-release formulation comprises:
- a core containing the and a biodegradable polymer, wherein the biodegradable polymer comprises at least one selected from the group consisting of:
- polylactide, polyglycolide, and poly (lactide-co-glycolide) as a copolymer of lactide and glycolide;
- and
- a coating layer coated on the core,
- the coating layer comprising at least one selected from the group consisting of basic amino acid, polypeptide and an organic nitrogen compound,
- wherein the subcutaneous administration of the composition results in a reduction in abnormal involuntary movements (AIMs) as assessed by an AIMs scoring system.
A method for prevention of levodopa-induced dyskinesia in a patient with a Parkinson's disease, the method comprising:
- subcutaneously administering a composition comprising a prophylactically effective amount of a controlled-release formulation of an exendin-4 or exenatide to the patient who does not involve occurrence of levodopa-induced dyskinesia,
- wherein the patient has received administration of levodopa,
- wherein the controlled-release formulation comprises:
- a core containing the exendin-4 or the exenatide- and a biodegradable polymer, wherein the biodegradable polymer comprises at least one selected from the group consisting of:
- polylactide, polyglycolide, and poly (lactide-co-glycolide) as a copolymer of lactide and glycolide;
- and
- a coating layer coated on the core, the coating layer comprising at least one selected from the group consisting of basic amino acid, polypeptide and an organic nitrogen compound,
- wherein the subcutaneous administration of the composition results in a reduction in abnormal involuntary movements (AIMs) as assessed by an AIMs scoring system.
Dependencies are inferred from the claim text.